SalioGen Therapeutics logo

SalioGen Therapeutics Funding & Investors

SalioGen Therapeutics advances in curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, a mammal-derived genome engineering technology. It is focused on providing durable, safe, and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platform’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.

saliogen.com

Total Amount Raised: $135,000,000

SalioGen Therapeutics Funding Rounds

  • Series B

    $115,000,000

    Series B Investors

    EPIQ Capital Group
    GordonMD Global Investments
    T. Rowe Price
    Cystic Fibrosis Foundation
    RD Fund
    Fidelity Investments
    D1 Capital Partners
    Symbiosis
  • Series A

    $20,000,000

    Series A Investors

    PBM Capital Group
Funding info provided by Diffbot.